COVID-19大流行期间重症医学临床试验适应的障碍、解决方案与机遇
本研究为混合方法研究,对加拿大重症试验组在COVID-19大流行期间开展的13项成人及儿科个体患者随机试验的主要研究者与项目协调员进行电子调查和焦点小组。障碍评分最高为暂停所有临床研究(均值4.7)、聚焦COVID-19研究(均值4.6)和限制家属探视(均值4.1)。作者建议提供科学领导、实施沟通与数据管理技术、简化知情同意、调整方案、促进中心参与、启动新中心、精简伦理与合同审查及设计嵌套研究。大流行增加了公众对重症与随机试验证据重要性的认识,并提示需要创新以确保试验严谨与完成。
要点
- 最高障碍为暂停所有临床研究(均值4.7)、聚焦COVID-19研究(均值4.6)和限制家属探视(均值4.1),均为5分制评分。
- 建议包括提供科学领导、实施沟通与数据管理技术、简化知情同意、调整方案、促进中心参与、启动新中心、精简伦理与合同审查及设计嵌套研究。
- 大流行促使新的资助机会以维持试验入组,并增加了公众对重症及随机试验证据重要性的认识。
- 作者认为大流行表明需要创新以确保进行中试验的严谨性与完成,优化研究程序的经验有助于未来临床试验体系。
适用人群与场景
- 加拿大重症试验组在COVID-19大流行期间开展成人及儿科个体患者随机试验的主要研究者与项目协调员。
- 纳入标准为2020年3月11日正在积极入组患者的试验。
研究设计与关键结果
- 研究类型为混合方法研究,采用解释性序贯分析,包括自填电子调查和焦点小组,共纳入13项试验,由29名主要研究者和项目协调员参与(参与率100%)。
- 障碍评分(5分制)最高为暂停所有临床研究(均值4.7,标准差0.8)、聚焦COVID-19研究(均值4.6,标准差0.8)和限制家属探视(均值4.1,标准差0.8)。
- 建议包括提供科学领导、实施沟通与数据管理技术、简化知情同意过程、必要时调整方案、促进中心参与、启动新中心、精简伦理与合同审查以及设计嵌套研究。
- 大流行促使新的资助机会以维持试验入组,并增加了公众对重症和随机试验证据重要性的认识。
证据类型、等级与局限
- 证据类型:混合方法研究(解释性序贯分析),整合定量调查与定性焦点小组数据。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者建议通过提供科学领导、实施沟通与数据管理技术、简化知情同意、调整方案、促进中心参与、启动新中心、精简伦理与合同审查及设计嵌套研究来支持试验推进与完成。
- 作者认为大流行表明需要创新以确保进行中试验的严谨性与完成。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The COVID-19 pandemic created unprecedented challenges for clinical trials worldwide, threatening premature closure and trial integrity. Every phase of research operations was affected, often requiring modifications to protocol design and implementation.
OBJECTIVES: To identify the barriers, solutions, and opportunities associated with continuing critical care trials that were interrupted during the pandemic, and to generate suggestions for future trials.
DESIGN, SETTING, AND PARTICIPANTS: This mixed-methods study performed an explanatory sequential analysis involving a self-administered electronic survey and focus groups of principal investigators (PIs) and project coordinators (PCs) conducting adult and pediatric individual-patient randomized trials of the Canadian Critical Care Trials Group during the COVID-19 pandemic. Eligible trials were actively enrolling patients on March 11, 2020. Data were analyzed between September 2023 and January 2024.
MAIN OUTCOMES AND MEASURES: Importance ratings of barriers to trial conduct and completion, solutions employed, opportunities arising, and suggested strategies for future trials. Quantitative data examining barriers were analyzed using descriptive statistics. Data addressing solutions, opportunities, and suggestions were analyzed by qualitative content analysis. Integration involved triangulation of data sources and perspectives about 13 trials, synthesized by an interprofessional team incorporating reflexivity and member-checking.
RESULTS: A total of 13 trials run by 29 PIs and PCs (100% participation rate) were included. The highest-rated barriers (on a 5-point scale) to ongoing conduct during the pandemic were decisions to pause all clinical research (mean [SD] score, 4.7 [0.8]), focus on COVID-19 studies (mean [SD] score, 4.6 [0.8]), and restricted family presence in hospitals (mean [SD] score, 4.1 [0.8]). Suggestions to enable trial progress and completion included providing scientific leadership, implementing technology for communication and data management, facilitating the informed consent process, adapting the protocol as necessary, fostering site engagement, initiating new sites, streamlining ethics and contract review, and designing nested studies. The pandemic necessitated new funding opportunities to sustain trial enrollment. It increased public awareness of critical illness and the importance of randomized trial evidence.
CONCLUSIONS AND RELEVANCE: While underscoring the vital role of research in society and drawing the scientific community together with a common purpose, the pandemic signaled the need for innovation to ensure the rigor and completion of ongoing trials. Lessons learned to optimize research procedures will help to ensure a vibrant clinical trials enterprise in the future.
参考来源
- Cook D, Taneja S, Krewulak K, et al. Barriers, Solutions, and Opportunities for Adapting Critical Care Clinical Trials in the COVID-19 Pandemic. JAMA Netw Open. 2024. PMID: 38995645. doi:10.1001/jamanetworkopen.2024.20458
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。